Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Bridion (sugammadex by Year
Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide sales ($M) ($M)
Merck Bridion (sugammadex: $1,841M in FY2025, up 4.4% from a year earlier.
Where the FY2025 figure comes from
“|| Bridion | 472 | 497 | 969 | 441 | 461 | 902 | 439 | 499 | 1,841 | 8 | 8 | 7 | 7”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,841 | +4.4% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 1,764 | -4.2% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 1,842 | +9.3% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 1,685 | +10.0% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 1,532 | +27.9% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 1,198 | +5.9% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 1,131 | +23.3% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 917 | +30.3% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 704 | +46.1% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 482 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up bridion (sugammadex
- Bridion (sugammadex — neuromuscular blockade reversal) — U.S. sales ($M)1,631 · FY2025
- Bridion (sugammadex — neuromuscular blockade reversal) — International sales ($M)209 · FY2025
- Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide reported growth YoY (%)4.0% · FY2025
- Bridion (sugammadex — neuromuscular blockade reversal) — Worldwide constant-currency (ex-exchange) growth YoY (%)4.0% · FY2025
Cite this data
StockData. (2026). Merck Bridion (sugammadex ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-bridion
See every metric in the Merck KPI table. Data updated Oct 26, 2026.